A5076871195- Cutaneous Melanoma Detection and Management
- Rheumatoid Arthritis Research and Therapies
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Molecular Biology Techniques and Applications
- BRCA gene mutations in cancer
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer, Lipids, and Metabolism
- Colorectal Cancer Screening and Detection
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Systemic Lupus Erythematosus Research
- Genetic factors in colorectal cancer
- Ethics in Clinical Research
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Diagnosis and Treatment
- Effects of Radiation Exposure
- Cytokine Signaling Pathways and Interactions
Myriad Genetics
2014-2024
Exact Sciences (United States)
2023-2024
Utah State University
2017
The University of Texas MD Anderson Cancer Center
2010
University of California, San Francisco
2010
Optimum management of clinically localised prostate cancer presents unique challenges because the highly variable and often indolent natural history disease. To predict disease aggressiveness, clinicians combine clinical variables to create prognostic models, but models have limited accuracy. We assessed value a predefined cell cycle progression (CCP) score in two cohorts patients with cancer. measured expression 31 genes involved CCP quantitative RT-PCR on RNA extracted from formalin-fixed...
The prevalence of BRCA(1/2) mutations in germline DNA from unselected ovarian cancer patients is 11% to 15.3%. It important determine the frequency somatic changes, given sensitivity BRCA-mutated cancers poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs.In 235 cancers, was sequenced 235, assessed by copy number analysis 95, tiling arrays 65. 113 tumors were for TP53. transcript levels quantitative polymerase chain reaction 220. When available with mutations,...
Histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. As a result, more sophisticated objective methods have been sought. The goal this study was to identify gene expression signature that reliably differentiated benign malignant lesions evaluate its potential clinical applicability. Herein, we describe the development validation using multiple independent cohorts representing broad spectrum histopathologic...
BACKGROUND Recently, a 23‐gene signature was developed to produce melanoma diagnostic score capable of differentiating malignant and benign melanocytic lesions. The primary objective this study independently assess the ability gene differentiate from nevi in clinically relevant METHODS A set 1400 lesions selected samples prospectively submitted for expression testing at clinical laboratory. Each sample tested subjected an independent histopathologic evaluation by 3 experienced...
Abstract Guideline recommended standard of care screening is available for four cancer types; most cancer-related deaths are caused by cancers without screening. DETECT-A the first prospective interventional trial evaluating a multi-cancer early detection (MCED) blood test (CancerSEEK) in women history cancer, providing opportunity to assess long-term outcomes individuals with false-positive (FP) MCED results. This analysis participants FP results evaluates performance an imaging-based...
In the US, <20% of cancers are diagnosed by standard-of-care (SoC) screening. Multicancer early detection (MCED) tests offer opportunity to expand cancer Understanding characteristics and clinical outcomes MCED-detected is critical clarifying MCED tests' potential impact. DETECT-A first prospective interventional trial an blood test (CancerSEEK). CancerSEEK, coupled with diagnostic PET-CT, identified including those not detected SoC screening, majority which were localized or regional. We...
Abstract Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi from melanoma. The current study assessed the performance this in independent cohort lesions against proven outcomes. Methods: Archival tissue primary cutaneous melanomas and obtained four institutions tested with gene signature. Cases were...
Abstract Background The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated two cohorts (OPERA BRASS) predicting risk radiographic progression. We now extend these findings with additional further validate score as a predictor progression compare its performance that other factors. Methods Four were analyzed: BRASS Leiden registries OPERA...
Abstract Background Neo-adjuvant chemotherapy (NaCT) facilitates complete surgical resection in locally advanced breast cancer. Due to its association with improved outcome, pathologic response (pCR) neo-adjuvant treatment has been accepted as a surrogate for long-term outcome clinical trials of human epidermal growth factor receptor 2 (HER2)-positive, triple-negative, or luminal B cancer patients. In contrast, NaCT is effective only ~ 7–10% estrogen (ER)-positive, HER2-negative disease....
Abstract Background Rheumatoid arthritis (RA) patients have increased risk for cardiovascular disease (CVD). Accurate CVD prediction could improve care RA patients. Our goal is to develop and validate a biomarker-based model predicting in Methods Medicare claims data were linked multi-biomarker activity (MBDA) test results create an patient cohort with age ≥ 40 years that was split 2:1 training internal validation. Clinical RA-related variables, MBDA score, its 12 biomarkers evaluated as...
Aim: These studies were to validate the analytical performance of a gene expression signature that differentiates melanoma and nevi, using RNA from 14 genes nine normalization generates diagnostic score (MDS). Materials & Methods: Formalin-fixed paraffin-embedded melanocytic lesions evaluated in these studies. Results: The overall SD assay was determined be 0.69 MDS units. Individual amplicons within had an average amplification efficiency 92% less than 0.5 CT. reproducible across 2000-fold...
Objective: To compare the multi-biomarker disease activity (MBDA) score with DAS28-CRP and CRP for predicting risk of radiographic progression in patients rheumatoid arthritis.Methods: Published studies MBDA ≥100 per cohort were evaluated. Rates over 1 year determined across low/moderate/high categories (low/moderate/high: <30, 30-44, >44), ≤2.67, >2.67-4.09, >4.09) ≤10, >10-30, >30 mg/L), positive negative predictive value (PPV, NPV) relative (RR) high vs. not-high (i.e. low moderate...
A 23-gene expression signature was recently developed as an adjunct to histopathology differentiate melanocytic nevi from melanoma. The current study correlated the gene scores actual clinical outcomes in cases first validation study. RNA extracted 127 archival formalin-fixed paraffin-embedded tissue sections of lesions. Gene measured using quantitative reverse-transcription polymerase chain reaction, and a weighting algorithm used generate numeric score. test results were compared...
Abstract Objective To develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account effects of age, sex adiposity in patients with RA. Methods Two models were developed adjust MBDA adiposity, using either serum leptin concentration or BMI as proxies adiposity. cohorts studied. A cohort 325 781 RA who had undergone commercial testing data was used both models. 1411 from five studies/registries only BMI-adjusted score. Univariate multivariate linear...
Aim: Evaluate the accuracy of a 23-gene expression signature in differentiating benign nevi from melanoma by comparing test results with clinical outcomes. Materials & methods: Seven dermatopathologists blinded to gene and outcomes examined 181 lesions identify diagnostically uncertain cases. Participants independently recorded diagnoses responses questions quantifying diagnostic certainty. Test was determined through comparison (sensitivity percent negative agreement). Results: Overall, 125...
The Multi-Biomarker Disease Activity (MBDA) score is a validated rheumatoid arthritis (RA) disease activity measure based on 12 serum biomarkers. Here, we evaluate short-term biological variability of MBDA scores to determine the magnitude change that might be considered clinically meaningful. Twenty-eight adult seropositive RA patients with stable and no changes in medications for 4 weeks prior study were enrolled. Nine samples obtained over four consecutive days (non-fasting). variation...
Previous studies have shown EndoPredict (EPclin), a test that integrates 12-gene expression data with nodal status and tumor size, to be predictive for risk of distant recurrence in women estrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Here, we modeled expected absolute chemotherapy benefit on the basis EPclin results.
To compare the prognostic capabilities and clinical utility of cell cycle progression (CCP) gene expression classifier test, multiparametric magnetic resonance imaging (mpMRI) with Prostate Imaging Reporting Data System (PI-RADS) scoring, clinicopathologic data in select prostate cancer (PCa) medical management scenarios.Retrospective, observational analysis patients (N = 222) ascertained sequentially from a single urology practice January 2015 to June 2018. Men were included if they had...
9021 Background: Histopathologic distinction between benign and malignant melanocytic tumors can be unreliable may lead to misdiagnosis. Measurement of biomarker gene expression has been proposed as an adjunctive diagnostic method in the evaluation ambiguous lesions with uncertain potential. This study aimed develop validate a signature capable accurately differentiating melanoma nevi. Methods: Seventy-nine candidate genes were identified based on changes previously observed or other cancer...
Validation of biomarker-based prognostic models to improve risk stratification in men with localized prostate cancer (PrCa) remains a clinical need. It has previously been shown that the cell cycle progression (CCP) test provides significant, independent information for who were incidentally diagnosed PrCa after transurethral resection (TURP) and conservatively managed.